selegiline-hydrochloride and Aldomet Interactions

Interactions between selegiline-hydrochloride(selegiline) and Aldomet (methyldopa)

methyldopa and selegiline (Major Drug-Drug)

CONTRAINDICATED: The coadministration of methyldopa and monoamine oxidase inhibitors (MAOIs) may result in loss of blood pressure control and/or signs of central stimulation such as hyperexcitability and hallucinations. The mechanism may involve excessive sympathetic stimulation in the central nervous system.

MANAGEMENT: Concurrent use of methyldopa with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with methyldopa.